{
    "id": "wrong_mix_range_foundationPlace_00059_1",
    "rank": 82,
    "data": {
        "url": "https://borlandgroover.com/physicians/kyle-etzkorn",
        "read_more_link": "",
        "language": "en",
        "title": "Dr. Kyle Etzkorn Gastroenterologist",
        "top_image": "",
        "meta_img": "",
        "images": [
            "https://borlandgroover.com/themes/contrib/myboot/images/BorlandGrooverLogo.svg",
            "https://borlandgroover.com/sites/default/files/inline-images/phone%20icon.png",
            "https://borlandgroover.com/sites/default/files/inline-images/coin-icon.png",
            "https://borlandgroover.com/sites/default/files/inline-images/calendar-icon.png",
            "https://borlandgroover.com/sites/default/files/2018-05/etzgray.jpg",
            "https://borlandgroover.com/themes/contrib/myboot/images/facebook.svg",
            "https://borlandgroover.com/themes/contrib/myboot/images/twitter.svg",
            "https://borlandgroover.com/themes/contrib/myboot/images/instagram.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "After completing his fellowship in gastroenterology and hepatology at the University of Texas Health Science Center/MD Anderson Cancer Center, Dr. Etzkorn completed an advanced fellowship in hepato-biliary medicine at the University of Illinois Hospital where he trained in advanced therapeutic procedures and the management of liver transplant patients.",
        "meta_lang": "en",
        "meta_favicon": "/sites/default/files/borland-icon.png",
        "meta_site_name": "",
        "canonical_link": "https://borlandgroover.com/physicians/kyle-etzkorn",
        "text": "Gane E, Shiffman M, Etzkorn KP. Sofosbuvir – Velpatasvir With Ribavirin for 24 Weeks in Hepatitis C Virus Patients Previously Treated with a Direct-Acting Antiviral Regimen, Hepatology, Vol 66, No 4, pages 1083-1089, 2017.\n\nKwo P, Gitlin N, Nahass, Bernstein D, Etzkorn KP. Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in Hepatitis C Virus Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1 in a Phase 3, Randomized Study, Hepatology, Vol 64, No 2, pages 370-380, 2016.\n\nGane E, Kowdley K, Pound D, Stedman C, Davis M, Etzkorn KP. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients with Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial, Gastroenterology, 151, pages 902-909, 2016.\n\nEverson G, Towner W, Davis M, Wyles D, Nahass R, Thuluvath P, Etzkorn KP. Sofosbuvir With Velpatasvir in Treatment-Naïve Noncirrhotic Patients with Genotype 1 to 6 Hepatitis C Virus Infection, Annals of Internal Medicine, Vol 163, No 11, pages 818-826, 2015.\n\nHernandez L, Deas T, Catalano M, Guda N, Huang L, Ketover S, Etzkorn KP. Longitudinal Assessment of Colonoscopy Quality Indicators: A Report from the Gastroenterology Practice Management Group, Gastrointestinal Endoscopy, Vol 80, No 5, pages 835-841, 2014.\n\nEtzkorn KP, Diab F, Rashid A, Dodda S, Brown RD, Venu RP. Endoscopic retrograde cholangiopancreatography under general anesthesia; Indications and results. Gastrointestinal Endoscopy 47(5)363-367,1998\n\nEtzkorn KP, Vitello J, McGuire DE, Resruck D, Venu RP, Watkins JL. A new technique for jejunal tube placement: A marriage of enteroscope and laparoscope. Gastrointestinal Endoscopy 43(6): 610-614, 1996.\n\nEtzkorn KP, Venu RP, Brown RD, McGuire DE, Abu-Hammour A. Saline injection needle knife sphincterotomy: A preliminary report. Endoscopy 28:360-364, 1996.\n\nGlaws WR, Etzkorn KP, Wenig BL, Zulfiqar H, Wiley TE, Watkins JL. Comparison of rigid and flexible esophagoscopy in the diagnosis of esophageal disease: Diagnostic accuracy, complications, and cost. Annals of Otology Rhinology Laryngology 105:262-265, 1996\n\nWatkins JL, Etzkorn KP, Wiley TE, DeGuzman LJ, Harig JM. Assessment of technical competence during ERCP training. Gastrointestinal Endoscopy 44(4) 411-415. 1996.\n\nMcGuire DE, Venu RP, Brown, RD, Etzkorn, KP, Glaws RW, Abu-Hammour A. Brush cytology for pancreatic carcinoma: An analysis of factors influencing results. Gastrointestinal Endoscopy 44(3) 300-304, 1996.\n\nAbu-Hammour A, Venu RP, Etzkorn KP, Shawel JL, Zaytsev PM, Brown RD. Common bile duct obstruction caused by multiple myeloma of the pancreas. Gastrointestinal Endoscopy 44(5) 606-608, 1996.\n\nEtzkorn KP, Brown RD, Mihalov M, Bavishi D. Acute colitis as complications of extracorporeal shock wave lithotripsy of renal calculi. Gastrointestinal Endoscopy(letter) 44(4) 511-512, 1996.\n\nEtzkorn KP, Mihalov M, Brown R, Bavishi D. Colonic Injury after ESWL of Renal Calculi, Gastrointestinal Endoscopy, pages 511-512, 1996.\n\nEtzkorn, KP, DeGuzman LD, Holderman WH, Abu-Hammour A, Schlesinger PK, Harig JM, Watkins JL. Endoscopic drainage of pancreatic pseudocysts: Patient selection and evaluation of outcome by endoscopic ultrasonography. Endoscopy 27:329-33, 1995\n\nHolderman WH, Etzkorn KP, Harig JM, Watkins JL. Endoscopic retrograde cholangiopancreatography and stent placement via gastrostomy: Technical aspects and clinical application. Endoscopy 27(1) 135-137, 1995.\n\nHolderman, WH, Etzkorn KP, Patel SA, Harig JM, Watkins JL. Endoscopic findings and complications associated with esophageal variceal ligation. Journal Clinical Gastroenterology 21(2) 91-94, 1995.\n\nEtzkorn KP, McGuire DE, Brown RD, Venu RP. Retrograde migration of PEG tubes. Gastrointestinal Endoscopy (Letter) 42(3) 279-280, 1995.\n\nVenu RP, Abu-Hammour A, Etzkorn KP, Loguidice JA. Sphincter of Oddi in health and disease. Revista De Gastrenterolgia De Mexico 59(2) 157-164, 1994.\n\nAbu-Hammour A, Venu RP, Etzkorn KP, McGuire DE, Brown RD, Watkins JL. Bile-alkaline phosphatase activity in cholestatic disorders. Gastroenterology(Submitted).\n\nAbstracts\n\nEtzkorn KP, Petterson JM. Double Balloon Enteroscopy in the Private Sector. Poster Presentation American College of Gastroenterology Scientific Meeting 2006. The American Journal of Gastroenterology A1290, S498. 101(9) 2006\n\nEtzkorn KP, Joglekar S, Kovacevic I, Fleisher M, Maniatis A, Sack T. Collagenous Colitis in a large community based GI pratice: Frequency, Workup, Treatment and Cost. Poster Presentation American College of Gastroenterology Scientific Meeting 2002\n\nEtzkorn KP, Kovacevic I, Joglekar S, Joseph B, Hoffman J, Carter M, Fleisher M. A Continuum of the aspiration technique in biliary type 3 sphincter of oddi manometry patients and the incidence of pancreatitis. Poster Presentation DDW 2002\n\nFleisher M, Rubin SD, Levine AE, Burnes A, Etzkorn KP, Turner R, Hopkins K. Infliximab in the treatment of steroid-naïve ulcerative colitis. Poster Presentation 66th Annual Scientific Meeting, American College of Gastroenterology, 2001. The American Journal of Gastroenterology A925, AJG 2001.\n\nFleisher M, Rubin SD, Levine AE, Burnes A, Etzkorn KP, Turner R, Hopkins K. Infliximab in the treatment of Crohn’s disease: Is it a steroid sparing agent or a steroid replacing agent?. Poster Presentation Presentation 66th Annual Scientific Meeting, American College of Gastroenterology, 2001. The American Journal of Gastroenterology A924, AJG 2001\n\nFleisher MR, Rubin SD, Sasson M, Zlatanic J, Burns A, Etzkorn KP. Remicade in the treatment of Refractory Extraintestinal Manifestations of Crohn’s Disease. Poster Presentation DDW American Gastroenterology Assocoiation 2001. Gastroenterology 3147, 2001\n\nDiab FH, Hibbeln KP, Etzkorn KP, Brown RD, Venu RP. Correlation of bile duct measurements by simultaneous ultrasound and cholangiogram. Poster Presentation at the American Gastroenterological Association, DDW 1997. Gastroenterology A503, 1997.\n\nEtzkorn KP, Watkins JL, Glaws WR, Halline AG, Bartolone CJ, Tripuraneni J, Wiley TEE, Pursell K. Evaluations of a non-endoscopic cytology balloon in the diagnosis of infectious esophageal disease in AIDS patients. Poster presentation at the American Gastroenterological Association, 1996. Gastroenterology A904, 1996\n\nEtzkorn KP, Diab FH, McGuire DE, Brown RD, Bedford R, Yotseff P, Venu RP. ERCP under general anesthesia: Indications and results. Poster presentation, ASGE 1996. Gastrointestinal Endoscopy A84, 1996.\n\nLi SD, Etzkorn KP, Goldsein JL, Sawhney M, Licke K, Magdaroag TV. Disposable endoscopic gowns: Do they add value? Poster presentation at the ASGE, DDW 1996. Gastrointestinal Endoscopy A106, 1996.\n\nBrown RD, Venu RP, Etzkorn KP, McGuire DE, Diab FH. Yield of endopancreatic cytology for pancreatic carcinoma varies widely by anatomic region of the pancreatic duct. Poster presentation at the ASGE, DDW 1996. Gastrointestinal Endoscopy A451, 1996.\n\nBarolone CJ, Venu RP, Brown RD, Etzkorn KP, Barboi A, Carr-Locke D. Defiant pancreatic calculi: A simplified therapeutic approach. Poster presentation at the ASGE, DDW 1996. Gastrointestinal Endoscopy A448, 1996.\n\nEtzkorn KP, Venu RP, Brown RD, McGuire DE, Abu-Hammour A. Cutting the papilla closer and safer: A new technique of needle knife sphincterotomy. Poster presentation at the American Society of Gastrointestinal Endoscopy, DDW May 1995. Gastrointestinal Endoscopy A4103, 1995.\n\nEtzkorn KP, Resnick D, Vitello J, Watkins JL, McGuire DE. A new technique for jejunal feeding tube placement: A marriage of enteroscope and laparoscope. Poster presentation at the American Society of Gastrointestinal Endoscopy, DDW May 1995. Gastrointestinal Endoscopy A543, 1995.\n\nWatkins JL, Etzkorn KP, Alam I, Block KP, Goldstein JL. Incomplete colonoscopy: Incidence, causes, and further evaluation. Poster presentation at the American Society of Gastrointestinal Endoscopy, DDW May 1995. Gastrointestinal Endoscopy A364, 1995.\n\nAbu-Hammour A, Etzkorn KP, Venu RP, Brown RD, McGuire DE, Watkins JL. New criteria for ERCP prior to laparoscopic cholecystectomy in-patients with non-severe acute gallstone pancreatitis. Poster presentation at the American Society of Gastrointestinal Endoscopy, DDW, May 1995. Gastrointestinal Endoscopy A367, 1995.\n\nMcGuire DE, Etzkorn KP, Hibbeln J, Aizzenstein R, Wiley TE, Owens C, Warner D, Layden TJ. A non-invasive method of determining portal hypertension: Correlation of hepatic arterial Doppler resistance values with hepatic wedge pressures and portal flow patterns in the cirrhotic liver. Poster presentation at the American Association for the Study of Liver Diseases, DDW May 1995. Gastroenterology A1120, 1995.\n\nAbu-Hammour A, Venu RP, Etzkorn KP, McGuire DE, Brown RD, Alam I, Watkins JL. Bile alkaline phosphate activity in cholestatic disorders. Poster presentation American Gastroenterological Association, DDW 1995. Gastroenterology A403, 1995.\n\nCass OW, Freeman ML, Cohen J, Zuckerman G, Fennerty M, Randall G, Jensen D, Nord J, Cerulli M, Etzkorn KP, Edmundowicz S, Lyche K, Watkins JL, Diehl LD, Cave D, Alkawas F, Locke GR, 14 fellowship ACES study group. Acquisition of competency in endoscopic skills (ACES) during training: Early results of a multicenter study. Poster presentation at the American Society of Gastrointestinal Endoscopy, DDW May 1995. Gastrointestinal Endoscopy A88, 1995.\n\nMcGuire DE, Brown RD, Venu RP, Etzkorn KP, Abu-Hammour A. Intraductal gentamicin during ERCP: Does it prevent cholangitis? Poster presentation at the American Society of Gastrointestinal Endoscopy, DDW May 19995. Gastrointestinal Endoscopy A444, 1995.\n\nMcGuire DE, Venu RP, Brown RD, Etzkorn KP, Abu-Hammour A, Glaws VR, Neal ER. Dual brush cytology: A technique to enhance tissue diagnosis of pancreatic cancer. Poster presentation at the American Society of Gastrointestinal Endoscopy, DDW May 1995. Gastrointestinal Endoscopy A522, 1995.\n\nBartolone C, DeGuzman LJ, Glaws WR, Etzkorn KP, Watkins JL. GI bleeding from lung cancer metastatic to the small intestine. Poster presentation at the American College of Gastroenterology October 1994. American Journal of Gastroenterology A84, 1994.\n\nEtzkorn KP, Abu-Hammour A, DeGuzman LJ, Watkins JL. Amebic liver abscess complicated by biliary leak. Poster presentation at the American College of Gastroenterology October 1994. American Journal of Gastroenterology A454, 1994.\n\nEtzkorn KP, DeGuzman LJ, Abu-Hammour A, Harig JM, Holderman WH, Watkins JL. Endoscopic drainage of pancreatic pseudocysts: Patient selection and evaluation of outcome by endoscopic Doppler ultrasonography. Poster presentation at the American College of Gastroenterology October 1994. American Journal of Gastroenterology A150, 1994.\n\nGlaws WR, Etzkorn KP, Weinig B, Zulfigas B, Wiley TE, Watkins JL. Comparison of rigid and flexible esophagoscopy in the diagnosis of esophageal disease: Diagnostic accuracy, complications, and costs. Poster presentation at the American College of Gastroenterology October 1994. American Journal of Gastroenterology A17, 1994.\n\nDeGuzman LJ, Etzkorn KP, Watkins JL. Hemangiopericytoma: An unusual cause of obstructive jaundice. Poster presentation at the American College of Gastroenterology October 1994. American Journal of Gastroenterology A442, 1994.\n\nGlaws WR, Etzkorn KP, Watkins JL, Venu RP. “Santorinicele” occurring in a patient with pancreas divisum presenting with chronic pancreatitis. Poster presentation at the American College of Gastroenterology October 1994. American Journal of Gastroenterology A460, 1994.\n\nEtzkorn KP, Venu RP, Reedy S, Sawhney M, Brown RD, Yotseff P, Bedford R. Does general anesthesia protect against ERCP induced severe pancreatitis? Gastroenterology A388, 1996.\n\nHarvey S, Michalov M, Etzkorn KP, Sawhney M, Brown RD, Resnick D, Vitello J, Venu RP. Endoscopic cystogastrostomy and bleeding: Is there histologic evidence for a predisposition to bleed? Gastrointestinal Endoscopy A469, 1996.\n\nDeGuzman LJ, Etzkorn KP, Watkins JL. Endoscopic ultrasonography: A universal Computer database modified from the endoscopy database (formerly ASGE Database). Poster presentation, DDW May 1994. Gastroenterology A9, 1994.\n\nAbu-Hammour A, Etzkorn KP, Venu RP, Wiley TE, DeGuzman, LP, Harig JM, Watkins JL. Acute gallstone pancreatitis: New guidelines from ERCP prior to laparoscopic cholecystectomy. Poster presentation World Congress of Gastroenterology October 1994.\n\nWatkins JL, DeGuzman LJ, Wiley TE, Etzkorn KP, Harig JM. ERCP training: Assessment of procedural competence. Gastroenterology A7, 1994.\n\nKazi S, Silas D, McGuire DE, Etzkorn KP, Venu RP. Discordance between interpretation of ERCP films by radiologists and gastroenterologists. Gastrointestinal Endoscopy A430, 1995.\n\nREVIEW ARTICLES AND NON-PEER REVIEWED PUBLICATIONS\n\nEtzkorn KP. What’s Hot in Gastroenterological Technology, Jacksonville Medicine 53(6) pages 209-213, 2002.\n\nEtzkorn KP. Book Review of Gastroenterologic Endoscopy, Gastrointestinal Endoscopy 53(2) pages 272-274, 2001.\n\nMcGuire DE, Venu RP, Abu-Hammour A, Etzkorn KP, Brown RD. Periampullary Disorders: A Review of Pathophysiology, The Gastroenterologist 3, pages 20-27, 1995.\n\nGlaws WR, Etzkorn KP, DeGuzman LJ, Steiner S, Bernardo D, Resnick DJ, Watkins JL. Endoscopic Treatment of Biliary Injuries Associated with Laparoscopic Cholecystectomy: The Chicago Experience, Journal of the Chicago Medical Society 97(12), pages 20-25, 1994.\n\nBOOK CHAPTERS\n\nEtzkorn KP. Constipation, Rodriguez L. Conn’s Current Therapy, 54th-2002 Edition, pages 18-20, W.B. Saunders.\n\nABSTRACTS AND POSTER PRESENTATIONS\n\nEtzkorn KP, Petterson JM, Double Balloon Enteroscopy in the Private Sector, poster presentation American College of Gastroenterology Scientific Meeting, 2006, The American Journal of Gastroenterology A1290, S498. 101(9), 2006.\n\nEtzkorn KP, Joglekar S, Kovacevic I, Fleisher M, Maniatis A, Sack T, Collagenous Colitis in a Large Community Based GI Practice: Frequency, Workup, Treatment and Cost, poster presentation American College of Gastroenterology Scientific Meeting, 2002.\n\nEtzkorn KP, Kovacevic I, Joglekar S, Joseph B, Hoffman J, Carter M, Fleisher M, A Continuum of the Aspiration Technique in Biliary Type 3 Sphincter of Oddi Manometry Patients and the Incidence of Pancreatitis, poster presentation, DDW 2002.\n\nFleisher M, Rubin SD, Levine AE, Burnes A, Etzkorn KP, Turner R, Hopkins K. Infliximab in the Treatment of Steroid-Naive Ulcerative Colitis, poster presentation, 66th Annual Scientific Meeting, American College of Gastroenterology, 2001, The American Journal of Gastroenterology A925, AJG 2001.\n\nFleisher M, Rubin SD, Levine AE, Burnes A, Etzkorn KP, Turner R, Hopkins K, Infliximab in the Treatment of Crohn’s Disease: Is it a Steroid Sparing Agent or a Steroid Replacing Agent? Poster Presentation, 66th Annual Scientific Meeting, American College of Gastroenterology, 2001, The American Journal of Gastroenterology A924, AJG, 2001.\n\nFleisher MR, Rubin SD, Sasson M, Zlatanic J, Burns A, Etzkorn KP, Remicade in the Treatment of Refractory Extraintestinal Manifestations of Crohn’s Disease, poster presentation, DDW American Gastroenterology Association, 2001, Gastroenterology 3147, 2001.\n\nDiab FH, Hibbeln KP, Etzkorn KP, Brown RD, Venu RP, Correlation of Bile Duct Measurements by Simultaneous Ultrasound and Cholangiogram, poster presentation at the American Gastroenterological Association, DDW 1997, Gastroenterology A503, 1997.\n\nEtzkorn KP, Watkins JL, Glaws WR, Halline AG, Bartolone CJ, Tripuraneni J, Wiley TEE, Pursell K, Evaluations of a Non-Endoscopic Cytology Balloon in the Diagnosis of Infectious Esophageal Disease in AIDS Patients, poster presentation at the American Gastroenterological Association, Gastroenterology A904, 1996.\n\nEtzkorn KP, Diab FH, McGuire DE, Brown RD, Bedford R, Yotseff P, Venu RP, ERCP under General Anesthesia: Indications and Results, poster presentation, ASGE, Gastrointestinal Endoscopy A84, 1996.\n\nLi SD, Etzkorn KP, Goldsein JL, Sawhney M, Licke K, Magdaroag TV, Disposable Endoscopic Gowns: Do They Add Value? poster presentation at the ASGE, DDW 1996, Gastrointestinal Endoscopy A106, 1996.\n\nBrown RD, Venu RP, Etzkorn KP, McGuire DE, Diab FH, Yield of Endopancreatic Cytology for Pancreatic Carcinoma Varies Widely by Anatomic Region of the Pancreatic Duct, poster presentation at the ASGE, DDW 1996, Gastrointestinal Endoscopy A451, 1996.\n\nBarolone CJ, Venu RP, Brown RD, Etzkorn KP, Barboi A, Carr-Locke D, Defiant Pancreatic Calculi: A Simplified Therapeutic Approach, poster presentation at the ASGE, DDW 1996, Gastrointestinal Endoscopy A448, 1996.\n\nEtzkorn KP, Venu RP, Reedy S, Sawhney M, Brown RD, Yotseff P, Bedford R, Does General Anesthesia Protect against ERCP Induced Severe Pancreatitis? Gastroenterology A388, 1996.\n\nHarvey S, Michalov M, Etzkorn KP, Sawhney M, Brown RD, Resnick D, Vitello J, Venu RP, Endoscopic Cystogastrostomy and Bleeding: Is There Histologic Evidence for a Predisposition to Bleed? Gastrointestinal Endoscopy A469, 1996.\n\nEtzkorn KP, Venu RP, Brown RD, McGuire DE, Abu-Hammour A, Cutting the Papilla Closer and Safer: A New Technique of Needle Knife Sphincterotomy, poster presentation at the American Society of Gastrointestinal Endoscopy, DDW May, 1995 Gastrointestinal Endoscopy A4103, 1995.\n\nEtzkorn KP, Resnick D, Vitello J, Watkins JL, McGuire DE, A New Technique for Jejunal Feeding Tube Placement: A marriage of Enteroscope and laparoscope, poster presentation at the American Society of Gastrointestinal Endoscopy, DDW May 1995, Gastrointestinal Endoscopy A543, 1995.\n\nWatkins JL, Etzkorn KP, Alam I, Block KP, Goldstein JL, Incomplete Colonoscopy: Incidence, Causes, and Further Evaluation, poster presentation at the American Society of Gastrointestinal Endoscopy, DDW May 1995, Gastrointestinal Endoscopy A364, 1995.\n\nAbu-Hammour A, Etzkorn KP, Venu RP, Brown RD, McGuire DE, Watkins JL, New Criteria for ERCP prior to Laparoscopic Cholecystectomy In-Patients with Non-Severe Acute Gallstone Pancreatitis, poster presentation at the American Society of Gastrointestinal Endoscopy, DDW May 1995, Gastrointestinal Endoscopy A367, 1995.\n\nMcGuire DE, Etzkorn KP, Hibbeln J, Aizzenstein R, Wiley TE, Owens C, Warner D, Layden TJ, A Non-Invasive Method of Determining Portal Hypertension: Correlation of Hepatic Arterial Doppler Resistance Values with Hepatic Wedge Pressures and Portal Flow Patterns in the Cirrhotic Liver, poster presentation at the American Association for the Study of Liver Diseases, DDW May 1995, Gastroenterology A1120, 1995.\n\nAbu-Hammour A, Venu RP, Etzkorn KP, McGuire DE, Brown RD, Alam I, Watkins JL, Bile Alkaline Phosphate Activity in Cholesteric Disorders, poster presentation American Gastroenterological Association, DDW 1995, Gastroenterology A403, 1995.\n\nCass OW, Freeman ML, Cohen J, Zuckerman G, Fennerty M, Randall G, Jensen D, Nord J, Cerulli M, Etzkorn KP, Edmundowicz S, Lyche K, Watkins JL, Diehl LD, Cave D, Alkawas F, Locke GR, 14 fellowship ACES study group, Acquisition of Competency in Endoscopic Skills (ACES) during Training: Early Results of a Multi-Center Study, poster presentation at the American Society of Gastrointestinal Endoscopy, DDW May 1995, Gastrointestinal Endoscopy A88, 1995.\n\nMcGuire DE, Brown RD, Venu RP, Etzkorn KP, Abu-Hammour, An Intraductal Gentamicin during ERCP: Does It Prevent Cholangitis? poster presentation at the American Society of Gastrointestinal Endoscopy, DDW May 1995, Gastrointestinal Endoscopy A444, 1995.\n\nMcGuire DE, Venu RP, Brown RD, Etzkorn KP, Abu-Hammour A, Glaws VR, Neal ER, Dual Brush Cytology: A Technique to Enhance Tissue Diagnosis of Pancreatic Cancer, poster presentation at the American Society of Gastrointestinal Endoscopy, DDW May 1995, Gastrointestinal Endoscopy A522, 1995.\n\nKazi S, Silas D, McGuire DE, Etzkorn KP, Venu RP, Discordance between Interpretation of ERCP Films by Radiologists and Gastroenterologists, Gastrointestinal Endoscopy A430, 1995.\n\nBartolone C, DeGuzman LJ, Glaws WR, Etzkorn KP, Watkins JL, GI Bleeding from Lung Cancer Metastatic to the Small Intestine, poster presentation at the American College of Gastroenterology, October 1994, American Journal of Gastroenterology A84, 1994.\n\nEtzkorn KP, Abu-Hammour A, DeGuzman LJ, Watkins JL, Amebic Liver Abscess Complicated by Biliary Leak, poster presentation at the American College of Gastroenterology, October 1994, American Journal of Gastroenterology A454, 1994.\n\nEtzkorn KP, DeGuzman LJ, Abu-Hammour A, Harig JM, Holderman WH, Watkins JL, Endoscopic Drainage of Pancreatic Pseudocysts: Patient Selection and Evaluation of Outcome by Endoscopic Doppler Ultrasonography, poster presentation at the American College of Gastroenterology, October 1994, American Journal of Gastroenterology A150, 1994.\n\nGlaws WR, Etzkorn KP, Weinig B, Zulfigas B, Wiley TE, Watkins JL, Comparison of Rigid and Flexible Esophagoscopy in the Diagnosis of Esophageal Disease: Diagnostic Accuracy, Complications, and Costs, poster presentation at the American College of Gastroenterology, October 1994, American Journal of Gastroenterology A17, 1994.\n\nDeGuzman LJ, Etzkorn KP, Watkins JL, Hemangiopericytoma: An Unusual Cause of Obstructive Jaundice. poster presentation at the American College of Gastroenterology, October 1994, American Journal of Gastroenterology A442, 1994.\n\nGlaws WR, Etzkorn KP, Watkins JL, Venu RP, “Santorinicele” Occurring in a Patient with Pancreas Divisum Presenting with Chronic Pancreatitis , poster presentation at the American College of Gastroenterology, October 1994, American Journal of Gastroenterology A460, 1994.\n\nDeGuzman LJ, Etzkorn KP, Watkins JL, Endoscopic ultrasonography: A Universal Computer Database Modified from the Endoscopy Database (formerly ASGE Database), poster presentation, DDW May 1994, Gastroenterology A9, 1994.\n\nAbu-Hammour A, Etzkorn KP, Venu RP, Wiley TE, DeGuzman, LP, Harig JM, Watkins JL, Acute Gallstone Pancreatitis: New Guidelines from ERCP prior to Laparoscopic Cholecystectomy, poster presentation, World Congress of Gastroenterology, October 1994.\n\nWatkins JL, DeGuzman LJ, Wiley TE, Etzkorn KP, Harig JM, ERCP Training: Assessment of Procedural Competence, Gastroenterology A7, 1994.\n\nPRESENTATIONS OF MATERIAL AT NATIONAL/INTERNATIONAL MEETINGS\n\nEtzkorn KP, faculty member presenting talks on: Double Balloon Enteroscopy, Sphincter of Oddi Manometry & The Difficult ERCP plus live video endoscopic demonstrations of Double Balloon Enteroscopy & ERCP, 1st Primer Curso Internacional de Endoscopia Digestiva Terapeutica, Bogota, Columbia, June 2006.\n\nEtzkorn KP, Advancements in Gastrointestinal Endoscopy III, Congreso Medico Boliviano-Americano, Sucre, Bolivia, June 1997.\n\nCass OW, Freeman ML, Cohen J, Zuckerman G, Watkins JL, Nord J, Locke GR, Jensen D, Diehl D, Cerulli M, Lyche K, Fennerty M, Edmundowicz S, Etzkorn KP, Al-Kawas F, Cave D, Lehman G, 14 fellowship ACES study group, Acquisition of Competency in Endoscopic Skills (ACES) during Training. A Multi-Center Study, oral and poster presentation at the ASGE DDW 1996, Gastrointestinal Endoscopy A72, 1996.\n\nEtzkorn KP, Watkins JL, Glaws WR, Halline AG, Bartolone CJ, Tripuraneni J, Wiley TE, Purcell K, Evaluation of Non-Endoscopic Cytology Balloon in the Diagnosis of Infectious Esophageal Disease in AIDS Patients, American College of Gastroenterology Annual Scientific Meeting, Seattle, Washington, October 1996.\n\nGlaws WR, Etzkorn KP, Wenig B, Zulfigar B, Wiley TE, Watkins JL, Comparison of Rigid and Flexible Esophagoscopy in the Diagnosis of Esophageal Disease: Diagnostic Accuracy, Complication, and Costs, American Broncho-Esopahgeological Association, Palm Springs, California, May 1995.\n\nEtzkorn KP, Resnick D, Vitello J, McGuire DE, Watkins JL, A New Technique for Jejunal Feeding Tube Placement: A Marriage of Enteroscope and Laparoscope, International Society of Minimally Invasive Therapeutics, Portland, Oregon, September 1995.\n\nORAL PRESENTATIONS AT CME/EDUCATIONAL COURSES\n\nUpdates in Endoscopy, Department of Surgery, Sihanouk Hospital, Phnom Penh, Cambodia, July 2010\n\nDouble Balloon Enteroscopy, all day lecture & live demonstration, Program Director, Baptist Medical Center and & Fuji Corporation, February 2007\n\nGastrointestinal and Liver Issues in Female Patients, Program Moderator, Baptist Medical Center, San Jose Country Club, Jacksonville, FL, February 2007\n\nDouble Balloon Enteroscopy & Sphincter of Oddi Dysfunction, SGNA Regional Course, Baptist Medical Center, Jacksonville, FL, February 2006\n\nNew Techniques in the Work Up of Small Bowel Disease Summit at Sea Level, sponsored by St. Vincent’s Medical Center, Ponte Vedra Inn & Club, March 2005\n\nHeme + Patient, New GERD Treatments, H. Pylori, Quarterly Grand Rounds, Department of Family Practice Baptist Health Care, February 2005\n\nColon Cancer 2005, American Cancer Society, Annual Board Meeting, San Jose Country Club, Jacksonville, FL, January 2005\n\nUpdates in Gastroenterology for Primary Care, Program Director, Sponsored by Baptist Medical Center, Jacksonville, FL, October 2004\n\nNausea & Vomiting in Diabetics: New Ideas for Pharmacotherapy, at “GI Hot Topics”, sponsored by St. Vincent’s Medical Center, Jacksonville, FL, June 2004\n\nAdvancement in ERCP: Stents, SOD Manometry, Pseudocysts, Annual Tri-State SGNA Meeting, Biloxi, Mississippi, October 2002\n\nNew Technologies in Gastroenterology, “GI Hot Topics 2002”, sponsored by St. Vincent’s Medical Center and the Borland-Groover Clinic, Jacksonville, FL, March 2002\n\nGastroenterology in Women’s Health, OB/GYN Grand Rounds, Department of Obstetrics and Gynecology, Baptist Medical Center, Jacksonville, FL, March 2002\n\nMedical Treatment of Acute & Chronic Pancreatitis, Fall Meeting of the FL Society of Health-System Pharmacists, University of North FL, Jacksonville, FL, November 2001\n\nUpdates in Gastroenterology & Hepatology, Orange Park Community Hospital Family Practice Grand Rounds, Orange Park, FL, October 2001\n\nAdvanced Therapeutics in the Community Setting, Focus on Access & Endoscopic Ultrasound, Update Wilson-Cook Symposium & The University of FL, Hilton Walt Disney World, Lake Beuna Vista, FL, April 2001\n\nTherapeutic Endoscopy and the role of MRCP & Virtual Colonoscopy, Jacksonville Fillipino Medical Society, Jacksonville, FL, February 2001\n\nHIV & HCV Co Infection, Annual HIV/AIDS Statewide Conference, University of FL Health Science Center Jacksonville, Department of Pediatrics, Jacksonville, FL, October 2000\n\nHepatitis C in The Psychiatric Patient Population, North FL State Hospital Noon Conference, MacClenny, FL, August 2000\n\nColon Cancer – 2000, Division of Family Practice, Noon Conference, St. Vincent’s Family Practice Residency Program, St. Vincent’s Hospital, Jacksonville, FL, May 2000\n\nCourse Director: Updates in Gastroenterology/Hepatology for the Primary Care Physician & Hands on Flexible Sigmoidoscopy Workshop, Borland-Groover Clinic & George Town University, Department of Continuing Medical Education, Hilton Towers and Hotel, Jacksonville, FL, April 2000\n\nColorectal Cancer & Women, Annual ALL THAT JAZZ Updates in OB-GYN, Omni Hotel, Jacksonville, FL, November 1999\n\nIrritable Bowel Syndrome in 1999, Department of Family Practice Noon Conference, St. Vincent’s Family Practice Residency, Jacksonville, FL, October 1999\n\nHep C Talk, FL Association of Health Maintenance Organizations, University Club, Jacksonville, FL, June 1999\n\nGI Hot Topics for Primary Care, St. Vincent’s Medical Center at Epping Forest Yacht Club, Jacksonville, FL, June 1999\n\nH. Pylori, & GERD Update, 23rd Annual CME Conference of the Georgia Association of Physician Assistants, Jekyll Island, Georgia, October, 1998\n\nAdvancement in Endoscopy, CME Meeting, Baptist-Beaches Hospital, Jacksonville Beach, FL, February 1997\n\nIrritable Bowel Syndrome, Medicine Lecture Series, Baptist Medical Center, Jacksonville, FL, November 1996\n\nAdvancements in Endoscopy: Utility or Futility, Department of Internal Medicine, Baptist Medical Center, Jacksonville, FL, August 1996\n\nColorectal Screening in Women, Department of Obstetrics and Gynecology, University of Illinois at Chicago, September 1995\n\nManagement of Cholangitis, Updates in Gastroenterology for Primary Care Physicians, sponsored by Trinity Medical Center, Moline, Illinois, September 1995\n\nEndoscopic Ultrasound: Today and the Future, GI Grand Rounds, Chicago Medical School, May 1995\n\nComplications of ERCP: Pancreatitis and Cholangitis, live videoconference, Advanced Therapeutic Pancreaticobiliary Endoscopy and Endoscopic Ultrasonography, Chicago Marriott, sponsored by the University of Illinois at Chicago, March 1995\n\nUpdate in the Management of Pseudocysts, Updates in Gastroenterology, Hyatt Regency Chicago, sponsored by University of Illinois Hospital, February 1995\n\nHIV and Dysphagia, Department of Family Practice, University of Illinois at Chicago, January 1995\n\nMASS MEDIA PRODUCTIONS\n\n“Get Tested” (Producer) Public Service Announcement Video, BGC & Channel 12, Jacksonville, FL, Spring 1999\n\n“Colon Cancer Testing” (Producer) Public Service Announcement Video, BGC & Channel 4, Jacksonville FL, Spring 1999\n\n“GERD & You” (Producer) Public Service Announcement Video, BGC & Channel 12, Jacksonville, FL, Spring 1999\n\nRESEARCH FUNDING (PRINCIPAL INVESTIGATOR)\n\nVibrant: A multi-national, multi-center, prospective double-blind, sham controlled, randomized study to assess the performance, efficacy, and safety of vibrating capsule medical device in relieving constipated individuals\n\nGS-US-367-1169: A phase 2, global, multi-center, randomized, open-label study to investigate the safety and efficacy of GS-9857 Plus Sofosbuvir/GS-5816 fixed-dose combination in subjects with chronic non-genotype 1 HCV infection\n\nGS-US-342-1137: A phase 3, multi-center, open-label study to Investigate the efficacy and safety of Sofosbuvir/GS-5816 fixed-dose combination in subjects with chronic HCV infection and child-Pugh class B cirrhosis\n\nGS-US-342-1446: An open-label study of Sofosbuvir/GS-5816 fixed-dose combination in subjects with chronic HCV infection\n\nGS-US-342-1553: An open-label study to evaluate the efficacy and safety of Sofosbuvir/GS-5816 fixed-dose combination with Ribavirin for 24 Weeks in chronic HCV infected subjects who participated in a prior Gilead sponsored HCV treatment study\n\nGS-US-342-1140: A phase 3, multi-center, randomized, open-label study to compare the efficacy and safety of Sofosbuvir/GS-5816 fixed-dose combination for 12 weeks with Sofosbuvir and Ribavirin for 24 weeks in subjects with chronic Genotype 3 HCV infection\n\nGS-US-342-1139: A phase 3, multi-center, randomized, open-label study to compare the efficacy and safety of Sofosbuvir/GS-5816 fixed-dose combination for 12 weeks with Sofosbuvir and Ribavirin for 12 weeks in subjects with chronic Genotype 2 HCV infection\n\nGS-US-342-1138: A phase 3, multi-center, randomized, double-blind study to investigate the efficacy and safety of Sofosbuvir/GS-5816 fixed-dose combination for 12 weeks in subjects with chronic HCV infection\n\nGS-US-337-1118: An open-label, multi-center study to evaluate the efficacy and safety of Sofosbuvir/Ledipasvir fixed-dose combination ± Ribavirin for 12 or 24 weeks In chronic Genotype 1 HCV infected subjects who participated in a prior\n\nGilead-sponsored HCV treatment study\n\nMK5172-052: A phase 2/3 randomized clinical trial to study the efficacy and safety of the combination regimen of MK-5172 and MK-8742 in subjects with chronic Hepatitis C virus infection and chronic kidney disease\n\nGS-US-342-0102: A phase 2, multi-center, randomized, open-label study to investigate the safety and efficacy of Sofosbuvir + GS-5816 for 12 weeks in treatment-naive subjects with chronic HCV infection\n\nGS-US-342-0109: A phase 2, multi-center, randomized, open-label study to investigate the safety and efficacy of Sofosbuvir + GS-5816 for 12 weeks in treatment-experienced subjects with chronic HCV infection\n\nGS-US-337-0108: A phase 3, multi-center, randomized, open-label study to investigate the efficacy and safety of Sofosbuvir/Ledipasvir fixed-dose combination ± Ribavirin for 8 weeks and Sofosbuvir/Ledipasvir fixed-dose combination for 12 weeks in treatment-naive subjects with chronic Genotype 1 HCV infection\n\nGS-US-337-0109: IONA phase 3, multi-center, randomized, open-label study to investigate the efficacy and safety of Sofosbuvir/GS-5885 fixed-dose combination ± Ribavirin for 12 and 24 weeks in treatment-experienced subjects with chronic Genotype 1 HCV infection\n\nM14-222: An open-label, multi-center study to evaluate long-term outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 with or without Ribavirin (RBV) in adults with Genotype 1 chronic Hepatitis C Virus (HCV) infection (TOPAZ II)\n\nM11-652: A randomized, open-label, multi-center study to evaluate the antiviral activity, safety, and pharmacokinetics of ABT-450 with Ritonavir (ABT-450/r) in combination with ABT-267 and/or ABT-333 with and without Ribavirin (RBV) for 8, 12 or 24 weeks in treatment-naive and null responder subjects with Genotype 1 chronic Hepatitis C virus infection\n\nGS-US-334-0107: A phase 3, multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of GS 7977 + Ribavirin for 12 weeks in subjects with chronic Genotype 2 or 3 HCV infection who are interferon intolerant, interferon ineligible, or unwilling to take interferon\n\nGS-US-334-0108: A phase 3, multi-center, randomized, double-blind, study to investigate the efficacy and safety of GS-7977 + Ribavirin for 12 or 16 weeks in treatment-experienced subjects with chronic Genotype 2 or 3 HCV infection\n\nGS-US-334-0109: (Re-Treatment) An open-label study to evaluate the safety of GS-7977 + Ribavirin for 12 weeks in subjects with chronic HCV infection who participated in a Gilead or Pharmasset sponsored clinical study of GS-7977 (PSI-7977)\n\nGS-US-334-0110: A phase 3, multi-center, open-label study to investigate the efficacy and safety of GS-7977 with Peginterferon Alfa 2a and Ribavirin for 12 weeks in treatment-naive subjects with chronic Genotype 1, 4, 5, or 6 HCV infection\n\nGS-US-248-0120: A phase 2 randomized, open-label study of GS-5885 administered concomitantly with GS-9451, Tegobuvir and Ribavirin (RBV) to treatment-naive subjects with chronic Genotype 1 HCV infection\n\nTMC435-HPC-3002: A prospective 3-year virological follow-up study in subjects previously treated in a phase 2b or phase 3 study with a TMC435-containing regimen for the treatment of hepatitis C virus (HCV) infection\n\nTMC435HPC3001: A phase 3, randomized, double-blind trial to evaluate the efficacy, safety, and tolerability of TMC435 vs. telaprevir, both in combination with PegIFNα-2a and ribavirin, in chronic Hepatitis C genotype-1 infected subjects who were null or partial responders to prior PegIFNα and Ribavirin therapy\n\nVX11-950-114: A phase 3b study of 2 treatment durations of Telaprevir, Peg-IFN (Pegasys®), and Ribavirin (Copegus®) in treatment-naive and prior relapser subjects With Genotype 1 chronic Hepatitis C and IL28B CC Genotype\n\nVX11-950-115: An open-label, phase 3 study of Telaprevir in combination with PegInterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in subjects co-infected with Genotype 1 Hepatitis C Virus and human immunodeficiency virus Type 1(HCV/HIV-1)\n\nVX08-950-112EXTEND: A 3-year, observational, virology follow-up study in subjects previously treated with telaprevir in select clinical studies\n\nVertex VX06-950-106: A Phase 2 study of Telaprevir (VX-950) in combination with Peginterferon Alfa-2 (Pegasys®), and Ribavirin (Copegus®) in subjects with Genotype 1 Hepatitis C who have not achieved sustained viral response with a prior course of interferon-based therapy\n\nVertex VX07-950-108: A Phase 3 study of 2 dose regimens of Telaprevir in combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in treatment-naive subjects with Genotype 1 chronic Hepatitis C\n\nA randomized, double-blind, Placebo-controlled evaluation study of the efficacy and pharmacokinetics of multiple doses of Basiliximab, with concomitant corticosteroids, in steroid-refractory ulcerative colitis\n\nCDP870-034: A phase 3 multi-national, multi-center, open-label, 52 week safety study to assess the safety of re-exposure after a variable interval and subsequent chronic therapy with the humanized anti-TNF PEG conjugate CDP870 400mg SC, (dosed at weeks 0, 2, and 4 and then 4 weekly to week 48), in the treatment of patients with active Crohn’s Disease who have previously been withdrawn from studies CDP870-031 or CDP870-032 due to an exacerbation of Crohn’s Disease\n\nA phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of three different doses (275, 550, and 1100mg) of Rifaximin administered for either two or four weeks in the treatment of patients with diarrhea-associated irritable bowel syndrome\n\nA phase 3, open-label, single arm study to assess the safety of Aquavan® (Fospropofol Disodium) injection for minimal to moderate sedation in patients undergoing minor surgical procedures\n\nA phase 3, multi-center, randomized, double-blind, placebo controlled, parallel-arm study of the efficacy and safety of OPC-6535 tablets in the treatment of subjects with active ulcerative colitis\n\nA phase 3, multi-center, open-label, extension study of the safety and efficacy of 25mg or 50mg of OPC-6535 oral tablets in the treatment of subjects with ulcerative colitis\n\nA phase 3, multi-center, randomized, double-blind, parallel-arm, 52 week dose comparison study of the efficacy and safety of 25mg QD of OPC-6535 oral tablets and 800mg bid of Asacol in the maintenance of remission in subjects with ulcerative colitis\n\nA randomized, open-labeled, multi-center, efficacy and safety study examining the effects of duration of treatment and of a high induction dose of PEGASYS® in combination with daily COPEGUS® in patients with chronic Hepatitis C who did not respond to previous Peginterferon alfa-2b/Ribavirin\n\nNovartis Pharmaceuticals Trial: A 6-week randomized, double-blind, double-dummy, placebo-controlled, multi-center study to assess the effect of tegaserod 2mg tid and 6mg tid on dyspeptic symptoms in diabetic patients with symptoms of diabetic gastrophy\n\nProtocol NV17317: randomized, multi-center, open-label, phase 4 study evaluating the efficacy and safety of 16 week versus 24 week treatment with PEGASYS® in combination with Copegus® in interferon-naive patients with chronic Hepatitis C Genotype 2 or 3 virus infection\n\nProtocol NV17318: A randomized, multi-center, double-blind, phase 4 pilot study evaluating the effect of PEGASYS® doses 180µg or 270µg in combination with Copegus® doses 1200mg or 1600mg on viral kinetics, virological response, pharmacokinetics, and safety in interferon-naive patients with chronic Hepatitis C Genotype 1 virus Infection of high viral titer and body weight greater than 85kg\n\nOP-2000: Incara Pharmaceutical LMH Ulcerative Colitis Study\n\nS-2413011: Solvay Pharmaceutical Diarrhea-IBS Predominant Study\n\nRebetol (Ribavirin) Hepatitis C treatment protocol in conjunction with the California Pacific Medical Center and Schering Pharmaceuticals\n\nM95-282: TAP Holdings, Inc., H.Pylori/Lansoprazole Sub-PI, University of Illinois\n\nM94-177: Abbott Laboratories – Duodenal Ulcer Study, University of Illinois\n\nNew Direct PEJ Placement System - Funding Corpac, University of Illinois\n\nAlpha-interferon therapy for C.A.H. and incidents of psychiatric phenomenon and attempts to prevent discontinuation of therapy with psychotherapeutic intervention - funding from Schering Pharmaceuticals, University of Illinois\n\nValeant rna003142-204: comparison of weight-based doses of Taribavirin combined with Peginterferon Alfa-2b versus Ribavirin combined with Perinterferon Alfa-2b in therapy-naive patients with chronic Hepatitis C Genotype 1 infection\n\nRESEARCH FUNDING (SUB-INVESTIGATOR)\n\nIntercept 747-303: A phase 3, double-blind, randomized, long-term, placebo-controlled, multi-center study evaluating the safety and efficacy of Obeticholic Acid in subjects with nonalcoholic steatohepatitis\n\nNovartis CLJN452A2202: A randomized, global, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of once-daily Oral Avatrombopag for the treatment of adults with Thrombocytopenia associated with Liver Disease prior to an elective procedure\n\nAbbott M14-490: Amendment 1 - An open-label, single-arm study to evaluate the safety and efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in adults with Genotype 1b chronic Hepatitis C virus (HCV) infection and cirrhosis (TURQUOISE-III)\n\nRHB-104-01: A phase 3, randomized, double-blind, placebo-controlled, multi-center, parallel group study to assess the efficacy and safety of fixed-dose combination RHB-104 in subjects with moderately to severely active Crohn’s Disease\n\nALV003-1221: A phase 2b, randomized, double-blind, placebo-controlled dose-ranging study of the efficacy and safety of ALV003 treatment in symptomatic Celiac Disease patients maintained on a Gluten-Free diet\n\nAI443-102: A phase 3 evaluation of a daclatasvir/asunaprevir/BMS-791325 fixed-dose combination in non-cirrhotic subjects with Genotype 1 chronic Hepatitis C\n\nAI443-113: A phase 3 evaluation of a daclatasvir/asunaprevir/BMS-791325 fixed-dose combination in subjects with Genotype 1 chronic Hepatitis C and compensated cirrhosis\n\nAmgen Protocol # 20110166: A randomized, double-blind, multi-dose, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 181 in subjects with moderate to severe Ulcerative Colitis\n\nAmgen Protocol # 20110232: A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 181 in subjects with moderate to severe Crohn’s Disease\n\nRoche NV18210: A randomized, multi-center, double-blind, phase 4 study evaluating the efficacy (as measured by sustained virological response) and safety of 360 mg Induction dosing of Pegasys in combination with higher Copegus doses in treatment-naive patients with chronic Hepatitis C Genotype 1 virus infection of high viral titer and baseline body weight greater than or equal to 85kg\n\nP&G 2007033: A phase 2, randomized, adaptive design, multi-center, parallel group, placebo-controlled, dose-ranging study of ATI-7505 in patients with Postprandial Distress Syndrome\n\nP&G 2007020 : A 52 week, randomized, double-blind, double-dummy, placebo-controlled study to assess the safety and efficacy of a 12 week treatment of acute diverticulitis with Asacol® 2.4g/day (400mg Mesalamine Tablet), followed by a nine month treatment-free observation period\n\nPsychometric evaluation of the nocturnal Gastroesophageal Reflux Disease questionnaire\n\nGenzyme 308180: phase 3, randomized, double-blinded, placebo-controlled, multi-center retreatment study of Sargramaostim (Leukine) in patients with active Crohn’s Disease and prior treatment response to Sargramostim\n\nA multi-center, randomized, double-blind, actively controlled trial to evaluate the safety and efficacy of a new tablet formulation and dosing regimen of Balsalazide Disodiun 3.3G bid versus Messalamine (5-ASA) as Asacol® 0.8G tid in mildly to moderately active Ulcerative Colitis\n\nA multi-center, open-label, treatment extension trial to evaluate the long-term safety and tolerability of Mesalamine Pellet formulation\n\nA multi-center, open-label study of the human anti-TNF monoclonal antibody adalimumab to evaluate the long-term safety and tolerability of repeated administration of Adalimumab in subjects with Crohn’s Disease\n\nCL-C002-00: A randomized, double-blind, multi-center, dose response, efficacy and safety evaluation of inflabloc cap in the treatment of patients with moderately active Crohn’s Disease\n\nA multi-center, randomized, double-blinded, placebo-controlled trial to evaluate the use of Mesalamine pellet formulation 1.5 QD to maintain remission from mild to moderate Ulcerative Colitis\n\nProtocol C0379T07: A multi-center, randomized, blinded, placebo-controlled, phase 2a study of human monoclonal antibody to Anti-IL-12p40 (CNTO 1275) in subjects with Crohn’s Disease inadequately controlled by 5-Aminosalcylates and/or Corticosteroids and open-label administration in subjects who are non-responders to anti-TNFα therapy\n\nA multi-center, randomized, double-blind, placebo-controlled study of the human anti-TNF monoclonal antibody Adalimumab for the induction of clinical remission in subjects with moderate to severe Crohn’s Disease who have Lost response or are intolerant to Infliximab\n\nCDP870-033: A phase 3, multi-national, multi-center, open-label, 52 week safety study to assess the safety of chronic therapy with the humanized anti-TNF PEG conjugate CDP870 400mg SC, (dosed 4 weekly to Week 48), in the treatment of patients with active Crohn’s Disease who have previously completed studies CDP870-031 or CDP870-032\n\nCDP870-031: A phase 3, multi-national, multi-center, double-blind, placebo-controlled parallel group, 26 week safety study to assess the safety and efficacy of the humanized anti-TNF PEG conjugate CDP870 400mg SC, (dosed at weeks 0, 2, 4 then 4 weekly to week 24), in the treatment of patients with active Crohn’s Disease\n\nA phase 3, double-masked, placebo-controlled study of Alicaforsen (ISIS 2302), and Antisense Inhibitor of ICAM-1, for the treatment of patient with active Crohn’s Disease\n\nA multi-center, placebo-controlled evaluation of the safety and efficacy of two dosage levels of OP2000 (75mg and 125mg) administered once daily by subcutaneous Infection for the treatment of active Ulcerative Colitis\n\nA phase 3, internationally, multi-center, double-blind, placebo-controlled study of the safety, efficacy, and tolerability of Intravenous Andregen TM (Natalizumab) (300mg monthly) in maintaining clinical response and remission in subjects with Crohn’s Disease\n\nA phase 3, double-masked, placebo-controlled study of Alicaforsen (Isis 2302, an Antisene Inhibitor of ICAM-1, for the treatment of patients with active Crohn’s Disease\n\nA phase 3, internationally, multi-center, double-blind, placebo-controlled, study of the safety, efficacy, and tolerability of intravenous Andregen TM (Natalizumab) in subjects with moderately to severely active Crohn’s Disease\n\nA 12-week, dose-ranging, double-blind, placebo-controlled study of Alosetron (GR68755) in subjects with Irritable Bowel Syndrome"
    }
}